sanjeri Biohaven ( NYSE: BHVN ) stock fell nearly 30% in premarket trading Wednesday after the company released new interim data from a Phase 1 study for its autoimmune drug candidate BHV-1300. Early Wednesday, Biohaven released updates on several of its drugs in development as part of its annual Investor R&D Day, including BHV-1300, BHV-2100, BHV-8000 and its weight-loss drug candidate taldefgrobep. The company also said it expects topline data in the second half of 2024 from a Phase 3 study for its drug myostatin in the treatment of spinal muscular atrophy.
Separately, Biohaven also announced that it had dosed the first patient in a Phase 1/2 study of its antibody drug conjugate BHV-1510 for the treatment of advanced or metastatic epithelial tumors. The company has also entered into a clinical supply agreement with Regeneron ( REGN ) to study BHV-1510 in combination with Regeneron’s anti-PD-1 drug Libtayo in the Phase 1/2 study. More on Biohaven Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge Biohaven drops 4%, prices $230M share offering Biohaven stock slides 15% amid data presentations Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohaven.
